CL Item

>= 18 Years Of Age (>= 18 years of age)

CL Item

>= 2 Weeks Since Prior Radiotherapy And All Toxicities Resolved (>= 2 weeks since prior radiotherapy and all toxicities resolved)

CL Item

Beta-hcg Negative (in Premenopausal Women) (Beta-Hcg negative (in premenopausal women))

CL Item

Bilirubin <= 1.5 X Uln Unless Due To Gilbert's Syndrome (Bilirubin <= 1.5 x ULN unless due to Gilbert's Syndrome)

CL Item

Bisphosphonate Therapy Allowed (Bisphosphonate therapy allowed)

CL Item

Creatinine <= 2.0 Mg/dl (Creatinine <= 2.0 mg/dl)

CL Item

Ecog (zubrod) Ps <= 1; Life Expectancy >=12 Wk (ECOG (Zubrod) PS <= 1; life expectancy >=12 wk)

CL Item

Granulocytes >= 1000/ul (Granulocytes >= 1000/ul)

CL Item

Histologic Dx Of Primary, Metastatic Stage Iv Or Locally Advanced, Unresectable Stage Iiib Cancer Of The Female Breast (using Ajcc Criteria, 6th Edition) Not Amenable To Local Therapy (Histologic dx of primary, metastatic Stage IV or locally advanced, unresectable Stage IIIB cancer of the female breast (using AJCC criteria, 6th edition) not amenable to local therapy)

CL Item

Inr <= 1.6, Unless On Full Dose Warfarin (INR <= 1.6, unless on full dose warfarin)

CL Item

Measurable/non-measurable Disease By Recist Criteria (Measurable/non-measurable disease by RECIST criteria)

CL Item

No Arterial Thrombotic Events, Tia, Cva, Acute Mi Or Unstable Angina Within 6 Months Of Registration (No arterial thrombotic events, TIA, CVA, acute MI or unstable angina within 6 months of registration)

CL Item

No Clinically Significant Cardiovascular Disease (No clinically significant cardiovascular disease)

CL Item

No Concurrent Active Secondary Malignancy (No concurrent active secondary malignancy)

CL Item

No History Of Abdominal Fistula Or Intraabdominal Abscess Within 6 Months Nor Gi Perforation Within 12 Months Of Registration (No history of abdominal fistula or intraabdominal abscess within 6 months nor GI perforation within 12 months of registration)

CL Item

No History Of Significant Bleeding Within 6 Months Of Registration (No history of significant bleeding within 6 months of registration)

CL Item

No Known Allergies To Aromatase Inhibitors Or Estrogen Receptor Modulators (No known allergies to aromatase inhibitors or estrogen receptor modulators)

CL Item

No Known Cns Metastases (No known CNS metastases)

CL Item

No Major Surgery Within 28 Days Of Registration (No major surgery within 28 days of registration)

CL Item

No Prior Bevacizumab Or Anti-vegf Therapy (No prior bevacizumab or anti-VEGF therapy)

CL Item

No Prior Chemotherapy For Metastatic Disease (No prior chemotherapy for metastatic disease)

CL Item

No Serious, Non-healing Wound, Ulcer Or Bone Fx (No serious, non-healing wound, ulcer or bone fx)

CL Item

Ovarian Suppression Required For Premenopausal Women (Ovarian suppression required for premenopausal women)

CL Item

Patients On Full Dose Anticoagulant Must Be On A Stable Dose Of Warfarin (Patients on full dose anticoagulant must be on a stable dose of warfarin)

CL Item

Platelet Count >= 100,000/ul (Platelet count >= 100,000/ul)

CL Item

Prior Adjuvant Or Neoadjuvant Chemotherapy Allowed (Prior adjuvant or neoadjuvant chemotherapy allowed)

CL Item

Prior Endocrine Therapy Not Required, But Is Permitted In Adjuvant Setting; No Prior Endocrine Therapy For Metastatic Disease Unless Initiated Within 4 Weeks Prior To Protocol Registration (Prior endocrine therapy not required, but is permitted in adjuvant setting; No prior endocrine therapy for metastatic disease unless initiated within 4 weeks prior to protocol registration)

CL Item

Transaminases (alt, Ast) <= 2.5 X Uln (Transaminases (ALT, AST) <= 2.5 x ULN)

CL Item

Tumors That Are Er And/or Pgr Positive (Tumors that are ER and/or PgR positive)

CL Item

Urinalysis <= 1+ Protein (Urinalysis <= 1+ protein)

CL Item

Women Can Be Either Pre- Or Postmenopausal (Women can be either pre- or postmenopausal)